论文部分内容阅读
目的研究急性冠脉综合症(ACS)患者血浆GMP-140的水平变化。方法随机选择ACS患者40例分为两个亚组:不稳定型心绞痛(UAP)20例为UAP组,急性心肌梗死(AMI)20例为AMI组,稳定型心绞痛(SAP)20例为SAP组,另外随机选择20例正常人作对照组。用酶联免疫双抗体夹心法(ELISA法)测定GMP-140的含量。结果(1)血浆GMP-140的含量在UAP组、AMI组均高于对照组(P<0.01)。(2)对照组与SAP组血浆GMP-140含量差异无显著性(P>0.05)。结论血浆GMP-140参与了ACS的病理、生理过程,并可以反映其严重程度,可作为监测ACS不稳定斑块的生化指标。
Objective To study the plasma level of GMP-140 in patients with acute coronary syndrome (ACS). Methods Forty ACS patients were randomly divided into two subgroups: UAP group (UAP group), UAP group (20 cases), AMI group (20 cases) and stable SAP group (20 cases) In addition, 20 normal individuals were randomly selected as the control group. The content of GMP-140 was determined by enzyme-linked immunosorbent assay (ELISA). Results (1) The content of plasma GMP-140 in UAP group and AMI group was higher than that in control group (P <0.01). (2) There was no significant difference in plasma GMP-140 levels between control group and SAP group (P> 0.05). Conclusion Plasma GMP-140 is involved in the pathology and physiology of ACS and can reflect its severity. It can be used as a biochemical indicator of unstable plaque in ACS.